Peripheral T-cell lymphoma, not otherwise specified, presenting with generalized ulcerated plaques and hypereosinophilia

Jani, Aditi; Innes, Matthew; Reddy, Vishnu; Prieto-Granada, Carlos; Graham, Lauren V.; Ergen, Elizabeth N.

doi:10.1016/j.jdcr.2018.05.013

Cited by 3 publications

(3 citation statements)

References 9 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The small number of cases may, however, be one reason for a lack of a significant difference in the survival curves between solitary vs. disseminated disease. The most common clinical presentation was nodules and tumours and less often papules, which was in line with the results of previous observations 1,14–20 …”

Section: Discussionsupporting

confidence: 92%

Primary cutaneous peripheral T‐cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico‐pathological and prognostic features

Kempf

Mitteldorf

Battistella

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Cutaneous peripheral T‐cell lymphoma, not otherwise specified (PTL NOS) is an aggressive, but poorly characterized neoplasm. Objectives The European Organization for Research and Treatment of Cancer cutaneous lymphoma taskforce (EORTC CLTF) investigated 33 biopsies of 30 patients with primary cutaneous PTL NOS to analyse their clinical, histological, immunophenotypic features and outcome. Methods Retrospective analysis of clinical data and histopathological features by an expert panel. Results Cutaneous PTL NOS manifested clinically either with solitary or disseminated rapidly grown ulcerated tumours or disseminated papulo‐nodular lesions. Histologically, a mostly diffuse or nodular infiltrate in the dermis and often extending into the subcutis was found. Epidermotropism was rarely present and only mild and focal. Unusual phenotypes were frequent, e.g. CD3+/CD4−/CD8− and CD3+/CD4+/CD8+. Moreover, 18% of the cases exhibited an aberrant expression of the B‐cell marker CD20 by the tumour cells. All solitary tumours were located on the limbs and presented a high expression of GATA‐3 but this did not correlate with outcome and therefore could not serve as a prognostic factor. The prognosis was shown to be generally poor with 10 of 30 patients (33%) dying of lymphoma within the follow‐up of 36 months (mean value; range 3–144). The survival rates were 61% after 3 years (CI, 43–85%) and 54% after 5 years (CI, 36–81%). Small to medium‐sized morphology of tumour cells was associated with a better outcome than medium to large or large tumour cells. Age, gender, clinical stage, CD4/CD8 phenotype and GATA‐3 expression were not associated with prognosis. Chemotherapy was the most common treatment modality, but surgical excision and/or radiotherapy may represent an appropriate first‐line treatment for solitary lesions. Conclusions Cutaneous PTL NOS shows an aggressive course in most patients independent of initial presentation, age and phenotype. Cytomorphology was identified as a prognostic factor. The data indicate a need for more effective treatment modalities in PTL NOS.

show abstract

Section: Discussionsupporting

confidence: 92%

Primary cutaneous peripheral T‐cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico‐pathological and prognostic features

Kempf

Mitteldorf

Battistella

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…1 It has a 16-36% 5-year disease specific survival rate. 6 In our case, high age, raised LDH levels, CD30 positivity were bad prognostic factor and she did not possess any risk for malignancy other than her age.…”

Section: Discussionmentioning

confidence: 47%

A rare case of peripheral T cell lymphoma, not otherwise specified with cutaneous involvement and diffuse systemic metastasis

2021

View full text Add to dashboard Cite

<p class="abstract">Peripheral T-cell lymphoma (PTCL), a subdivision of T-cell non-Hodgkin lymphomas (NHLs), is rare and different from the more common cutaneous T-cell lymphomas. PTCL is a diverse group of disorders and carries a poor prognosis. Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) is the most common and aggressive disorder out of the group, which involves the lymph nodes followed by the skin, liver, and gastrointestinal tract. We hereby report a case of a 60 years old female who presented to us with complaints of multiple painful dark-coloured nodular lesions and indurated plaques over bilateral upper limbs, lower limbs and trunk, for 3 months. After detail laboratory investigations, histopathological and immunohistochemistry which was positive for CD30 antigen we confirmed the diagnosis as PTCL-NOS. Radiological imaging showed involvement of gastrointestinal tract, adrenal gland and vertebrae. After thorough workup the patient was started on palliative radiotherapy, unfortunately she succumbed to death. In conclusion, PTCL-NOS with CD30 positivity is rare and aggressive with a poor prognosis, it is important to identify such cases and work in conjugation with an oncologist for proper management.</p>

show abstract

“…About 35%-45% of cases were diagnosed with B symptoms, including fever, systemic lymphadenopathy, fatigue, and unexplained weight loss. Sometimes, pruritus, eosinophilia, and hemophagocytic syndrome may be characteristic of this disease[9,10]. Extranodal lesions can occur in approximately half of the cases, with the skin and gastrointestinal tract being the most frequently affected extranodal sites.…”

mentioning

confidence: 99%

PD-1 Antibody Combined With Decitabine Is Effective in the Treatment of Refractory Peripheral T-cell Lymphoma Not Otherwise Specified: a Case Report

Han

Qin

Liu

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is a highly aggressive lymphoma with a poor response to chemotherapy, frequent relapses, low overall survival, and poor prognosis, and is the most common form of PTCL. For relapsed/refractory (R/R) PTCLs, the efficacy of traditional chemotherapy is even worse, so clinical trials and new drugs become their therapeutic hopes. Here, We report on a 43-year woman with refractory PTCL-NOS has a good response to PD-1 antibody combined with decitabine. Case presentation: A 43-year-old woman with refractory PTCL-NOS, who has a poor efficacy in the first-line and second-line treatments, even the disease progresses after treatment with histone deacetylase inhibitors and proteasome inhibitors, however, has a good response to PD-1 antibody combined with decitabine. The patient got significant tumor regression and some of the masses even disappeared.Conclusions: The PD-1 monoclonal antibody combined with decitabine may be a good choice to improve prognosis when used early if conventional first- and second-line regimens, histone deacetylase inhibitors, and proteasome inhibitors are ineffective.

show abstract

Peripheral T-cell lymphoma, not otherwise specified, presenting with generalized ulcerated plaques and hypereosinophilia

Cited by 3 publications

References 9 publications

Primary cutaneous peripheral T‐cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico‐pathological and prognostic features

Primary cutaneous peripheral T‐cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico‐pathological and prognostic features

A rare case of peripheral T cell lymphoma, not otherwise specified with cutaneous involvement and diffuse systemic metastasis

PD-1 Antibody Combined With Decitabine Is Effective in the Treatment of Refractory Peripheral T-cell Lymphoma Not Otherwise Specified: a Case Report

Contact Info

Product

Resources

About